{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immunogenicity%2C+Vaccine&page=2",
    "query": {
      "condition": "Immunogenicity, Vaccine",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immunogenicity%2C+Vaccine&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-11T02:19:22.270Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01263691",
      "title": "Safety, Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Bacillus Anthracis (Anthrax) Infection"
      ],
      "interventions": [
        {
          "name": "BioThrax",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AV7909 Formulation 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AV7909 Formulation 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AV7909 Formulation 3",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AV7909 Formulation 4",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Control",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Emergent BioSolutions",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 105,
      "start_date": "2010-12",
      "completion_date": "2012-06",
      "has_results": true,
      "last_update_posted_date": "2024-03-18",
      "last_synced_at": "2026-06-11T02:19:22.270Z",
      "location_count": 3,
      "location_summary": "Miami, Florida • Raleigh, North Carolina • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Raleigh",
          "state": "North Carolina"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01263691"
    },
    {
      "nct_id": "NCT00459316",
      "title": "Safety of and Immune Response to a Meningitis Vaccine in HIV-Infected Children and Youth",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections",
        "Meningitis"
      ],
      "interventions": [
        {
          "name": "Quadrivalent meningococcal conjugate vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "24 Years",
        "sex": "ALL",
        "summary": "2 Years to 24 Years"
      },
      "enrollment_count": 384,
      "start_date": "2007-06",
      "completion_date": "2013-03",
      "has_results": true,
      "last_update_posted_date": "2021-11-03",
      "last_synced_at": "2026-06-11T02:19:22.270Z",
      "location_count": 35,
      "location_summary": "Alhambra, California • Long Beach, California • Los Angeles, California + 25 more",
      "locations": [
        {
          "city": "Alhambra",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00459316"
    },
    {
      "nct_id": "NCT00307710",
      "title": "Influenza Vaccination in Patients Receiving Antineoplastic Therapy for Non-Hodgkin's Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "Trivalent Baculovirus-expressed Influenza HA vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2004-08",
      "completion_date": "2007-02",
      "has_results": false,
      "last_update_posted_date": "2012-07-31",
      "last_synced_at": "2026-06-11T02:19:22.270Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00307710"
    },
    {
      "nct_id": "NCT00395174",
      "title": "Comparison of the Immunogenicity, Safety and Reactogenicity of FluBlok, To a Licensed Vaccine In Elderly Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Influenza Vaccination",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Protein Sciences Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 870,
      "start_date": "2006-10",
      "completion_date": "2007-05",
      "has_results": false,
      "last_update_posted_date": "2009-12-17",
      "last_synced_at": "2026-06-11T02:19:22.270Z",
      "location_count": 7,
      "location_summary": "Baltimore, Maryland • Rochester, Minnesota • Shrewsbury, New Jersey + 3 more",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Shrewsbury",
          "state": "New Jersey"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00395174"
    },
    {
      "nct_id": "NCT00382980",
      "title": "Dose-Escalating Trial Using Vero Cell-culture Derived H5N1 +/- Aluminum in Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Aluminum hydroxide",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Inactivated Vero cell based whole virus influenza A/H5N1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 308,
      "start_date": "2006-10",
      "completion_date": "2007-09",
      "has_results": false,
      "last_update_posted_date": "2010-08-27",
      "last_synced_at": "2026-06-11T02:19:22.270Z",
      "location_count": 5,
      "location_summary": "Stanford, California • Torrance, California • Baltimore, Maryland + 2 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00382980"
    },
    {
      "nct_id": "NCT00000868",
      "title": "A Study to Evaluate the Safety and Effectiveness of HIV-1 LAI gp120 (an HIV Vaccine) Given With or Without HIV-1 MN rgp120 (Another HIV Vaccine) to HIV-Negative Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections",
        "HIV Seronegativity"
      ],
      "interventions": [
        {
          "name": "Salmonella typhi CVD 908-HIV-1 LAI gp 120 (VVG 203)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Aluminum hydroxide",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rgp120/HIV-1MN",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 27,
      "start_date": null,
      "completion_date": "2000-05",
      "has_results": false,
      "last_update_posted_date": "2021-10-28",
      "last_synced_at": "2026-06-11T02:19:22.270Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000868"
    },
    {
      "nct_id": "NCT02955160",
      "title": "A Phase 1, Randomized, Controlled, Observer-blinded Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Healthy Adults Aged 18 to 49 Years",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pneumococcal Infections"
      ],
      "interventions": [
        {
          "name": "Multivalent",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tdap",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 66,
      "start_date": "2016-11-03",
      "completion_date": "2017-08-01",
      "has_results": false,
      "last_update_posted_date": "2018-09-11",
      "last_synced_at": "2026-06-11T02:19:22.270Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02955160"
    },
    {
      "nct_id": "NCT01537185",
      "title": "Phase I Safety Trial of Streptococcus Pneumoniae Whole Cell Vaccine (SPWCV) + Alum in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pneumococcal Vaccines"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "SPWCV+Alum 100 mcg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SPWCV+Alum 600 mcg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SPWCV+Alum 300 mcg",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "PATH Vaccine Solutions",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 42,
      "start_date": "2012-02",
      "completion_date": "2013-04",
      "has_results": true,
      "last_update_posted_date": "2014-06-05",
      "last_synced_at": "2026-06-11T02:19:22.270Z",
      "location_count": 1,
      "location_summary": "Tacoma, Washington",
      "locations": [
        {
          "city": "Tacoma",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01537185"
    },
    {
      "nct_id": "NCT06087640",
      "title": "A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Influenza, Human"
      ],
      "interventions": [
        {
          "name": "aQIV or aTIV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "QIV or TIV",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Seqirus",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 35800,
      "start_date": "2023-10-23",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-06-01",
      "last_synced_at": "2026-06-11T02:19:22.270Z",
      "location_count": 111,
      "location_summary": "Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 95 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06087640"
    },
    {
      "nct_id": "NCT04199689",
      "title": "Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Papillomavirus Infections"
      ],
      "interventions": [
        {
          "name": "9vHPV Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (Saline for Injection)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "45 Years",
        "sex": "MALE",
        "summary": "20 Years to 45 Years · Male only"
      },
      "enrollment_count": 6033,
      "start_date": "2020-02-27",
      "completion_date": "2028-08-31",
      "has_results": false,
      "last_update_posted_date": "2025-03-25",
      "last_synced_at": "2026-06-11T02:19:22.270Z",
      "location_count": 32,
      "location_summary": "Northridge, California • Rialto, California • Simi Valley, California + 28 more",
      "locations": [
        {
          "city": "Northridge",
          "state": "California"
        },
        {
          "city": "Rialto",
          "state": "California"
        },
        {
          "city": "Simi Valley",
          "state": "California"
        },
        {
          "city": "Spring Valley",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04199689"
    }
  ]
}